Logo image of ATRA

ATARA BIOTHERAPEUTICS INC (ATRA) Stock Fundamental Analysis

NASDAQ:ATRA - Nasdaq - US0465132068 - Common Stock - Currency: USD

11.22  -0.1 (-0.88%)

Premarket: 11.58 +0.36 (+3.21%)

Fundamental Rating

2

Taking everything into account, ATRA scores 2 out of 10 in our fundamental rating. ATRA was compared to 551 industry peers in the Biotechnology industry. Both the profitability and financial health of ATRA have multiple concerns. While showing a medium growth rate, ATRA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ATRA has reported negative net income.
In the past year ATRA has reported a negative cash flow from operations.
ATRA had negative earnings in each of the past 5 years.
ATRA had a negative operating cash flow in each of the past 5 years.
ATRA Yearly Net Income VS EBIT VS OCF VS FCFATRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -25.21%, ATRA is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
ATRA's Return On Invested Capital of 4.91% is amongst the best of the industry. ATRA outperforms 93.10% of its industry peers.
Industry RankSector Rank
ROA -25.21%
ROE N/A
ROIC 4.91%
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATRA Yearly ROA, ROE, ROICATRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

With an excellent Operating Margin value of 0.44%, ATRA belongs to the best of the industry, outperforming 90.93% of the companies in the same industry.
Looking at the Gross Margin, with a value of 80.24%, ATRA belongs to the top of the industry, outperforming 85.48% of the companies in the same industry.
Industry RankSector Rank
OM 0.44%
PM (TTM) N/A
GM 80.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATRA Yearly Profit, Operating, Gross MarginsATRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ATRA is destroying value.
The number of shares outstanding for ATRA has been increased compared to 1 year ago.
ATRA has less shares outstanding than it did 5 years ago.
The debt/assets ratio for ATRA is higher compared to a year ago.
ATRA Yearly Shares OutstandingATRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATRA Yearly Total Debt VS Total AssetsATRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

ATRA has an Altman-Z score of -42.26. This is a bad value and indicates that ATRA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -42.26, ATRA is doing worse than 91.47% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -42.26
ROIC/WACC0.52
WACC9.4%
ATRA Yearly LT Debt VS Equity VS FCFATRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

ATRA has a Current Ratio of 0.57. This is a bad value and indicates that ATRA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ATRA (0.57) is worse than 92.01% of its industry peers.
A Quick Ratio of 0.57 indicates that ATRA may have some problems paying its short term obligations.
ATRA's Quick ratio of 0.57 is on the low side compared to the rest of the industry. ATRA is outperformed by 92.01% of its industry peers.
Industry RankSector Rank
Current Ratio 0.57
Quick Ratio 0.57
ATRA Yearly Current Assets VS Current LiabilitesATRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

ATRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.01%, which is quite impressive.
The Revenue has grown by 475.45% in the past year. This is a very strong growth!
The Revenue has been growing by 85.07% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160.87%
Revenue 1Y (TTM)475.45%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%258.77%

3.2 Future

Based on estimates for the next years, ATRA will show a very strong growth in Earnings Per Share. The EPS will grow by 20.75% on average per year.
ATRA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.85% yearly.
EPS Next Y87.73%
EPS Next 2Y33.61%
EPS Next 3Y20.69%
EPS Next 5Y20.75%
Revenue Next Year-41.79%
Revenue Next 2Y-47.57%
Revenue Next 3Y-41.47%
Revenue Next 5Y9.85%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ATRA Yearly Revenue VS EstimatesATRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ATRA Yearly EPS VS EstimatesATRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATRA Price Earnings VS Forward Price EarningsATRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ATRA indicates a rather cheap valuation: ATRA is cheaper than 95.10% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.26
ATRA Per share dataATRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

ATRA's earnings are expected to grow with 20.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.61%
EPS Next 3Y20.69%

More info and screens

0

5. Dividend

5.1 Amount

ATRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATARA BIOTHERAPEUTICS INC

NASDAQ:ATRA (8/5/2025, 8:00:00 PM)

Premarket: 11.58 +0.36 (+3.21%)

11.22

-0.1 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners51.71%
Inst Owner Change0.01%
Ins Owners2.35%
Ins Owner Change1.58%
Market Cap75.06M
Analysts80
Price Target15.64 (39.39%)
Short Float %5.16%
Short Ratio4.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)170.35%
Min EPS beat(2)67.38%
Max EPS beat(2)273.33%
EPS beat(4)2
Avg EPS beat(4)49.39%
Min EPS beat(4)-94.51%
Max EPS beat(4)273.33%
EPS beat(8)5
Avg EPS beat(8)24.85%
EPS beat(12)6
Avg EPS beat(12)12.03%
EPS beat(16)8
Avg EPS beat(16)7.86%
Revenue beat(2)2
Avg Revenue beat(2)832.89%
Min Revenue beat(2)67.7%
Max Revenue beat(2)1598.08%
Revenue beat(4)3
Avg Revenue beat(4)412.01%
Min Revenue beat(4)-29.79%
Max Revenue beat(4)1598.08%
Revenue beat(8)4
Avg Revenue beat(8)182.71%
Revenue beat(12)5
Avg Revenue beat(12)157.39%
Revenue beat(16)7
Avg Revenue beat(16)118.04%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)42.98%
EPS NQ rev (3m)66.67%
EPS NY rev (1m)68.92%
EPS NY rev (3m)68.92%
Revenue NQ rev (1m)-1.76%
Revenue NQ rev (3m)-1.76%
Revenue NY rev (1m)95.29%
Revenue NY rev (3m)95.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.38
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 16.26
EPS(TTM)-3.72
EYN/A
EPS(NY)-2.79
Fwd EYN/A
FCF(TTM)-10.07
FCFYN/A
OCF(TTM)-10.05
OCFYN/A
SpS29.86
BVpS-8.23
TBVpS-8.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.21%
ROE N/A
ROCE 6.22%
ROIC 4.91%
ROICexc 227.93%
ROICexgc 227.93%
OM 0.44%
PM (TTM) N/A
GM 80.24%
FCFM N/A
ROA(3y)-101.92%
ROA(5y)-86.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover3.22
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 6.42
Cap/Depr 2.18%
Cap/Sales 0.06%
Interest Coverage 1.38
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.57
Quick Ratio 0.57
Altman-Z -42.26
F-Score3
WACC9.4%
ROIC/WACC0.52
Cap/Depr(3y)34.79%
Cap/Depr(5y)54.33%
Cap/Sales(3y)7.02%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160.87%
EPS Next Y87.73%
EPS Next 2Y33.61%
EPS Next 3Y20.69%
EPS Next 5Y20.75%
Revenue 1Y (TTM)475.45%
Revenue growth 3Y85.07%
Revenue growth 5YN/A
Sales Q2Q%258.77%
Revenue Next Year-41.79%
Revenue Next 2Y-47.57%
Revenue Next 3Y-41.47%
Revenue Next 5Y9.85%
EBIT growth 1Y100.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.45%
EBIT Next 3Y12.47%
EBIT Next 5Y-3.99%
FCF growth 1Y70.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.03%
OCF growth 3YN/A
OCF growth 5YN/A